Tutkimus

Oulun yliopiston syöpätautien ja sädehoidon klinikan väitöskirjat 2000-2007

• 2000 Kallio Raija: Traditional and new markers of infection in adult cancer patients and the possible interfering effect of underlying malignancy on these markers.
• 2003 Kuittinen Outi: Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in hematological malignancies.
• 2005 Ruokolainen Henni: The prognostic role of matrix metalloproteinase -2 and -9 (MMP-2, MMP-9) and their tissue inhibitors -1 and -2 (TIMP-1, TIMP-2) in head and neck squamous cell carcinoma.
• 2006 Rauvala Marita: Matrix metalloproteinases -2 and -9 and tissue inhibitors of metalloproteinases -1 and -2 in gynaecological cancers.
• 2007 Rahko Eeva: Evaluation of tumor suppressor gene p53, oncogene c-erbB-2 and matrix-metalloproteinase-9 as prognostic and predictive factors in breast carcinoma.
  

Julkaisuja 2000-2007

• Honkavuori M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T & Santala M. MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gynecologic Oncology 2007;104:217-221.
• Sillanpää S, Anttila M, Voutilainen T, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, Tammi R, Tammi M, Sironen R, Saarikoski S & Kosma V-M. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecologic Oncology 2007;104;296-303.
• Kuvaja P, Talvensaari-Mattila A &Turpeenniemi-Hujanen T. The sample type used affects the levels of gelatinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in circulating blood of healthy controls and breast cancer patients. Biomarker Insights 2007;2:117-127.
• Ruokolainen H, Pääkkö P & Turpeenniemi-Hujanen T. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma - tissue immunoreactivity predicts aggressive clinical course. Modern Pathology 2006;19:208-217.
• Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al., Turpeenniemi-Hujanen Taina , et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20
• Ruokolainen H, Pääkkö P & Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 2005;116:422-427.
• Ruokolainen H, Pääkkö P & Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma - comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res 2005;11:3257-3264.
• Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimäki A, Turpeenniemi-Hujanen T. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Research and Treatment 2005;89:215-220.
• Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Research and Treatment 2005;89:29-34.
• Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005;87:287-297.
• Ruokolainen H, Pääkkö P & Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004;10:3110-3116.
• Huusko P, Juo S-HH, Gilladers E, Sarantaus L, Kainu T, Vahteristo P, Allinen M, Jones M, Rapakko K, et al. Leisti J, Blanco G, Winqvist R. Genome-wide scanning for linkage in Finnish breast cancer families. European Journal of Human Genetics 2004;12(2):98-104.
• Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocrine-Related Cancer 2004;11:571-579.
• Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J. Risk for distant recurrence of breast cancer detected by mammography screenin or other methods. JAMA. 2004;292(9):1064-1073.
• Mackey AL, Donnelly AE, Turpeenniemi-Hujanen T, Roper HP. Skeletal muscle collagen content in humans after high-force eccentric contractions. Journal of Applied Physiology 2004;97:197-203.
• Hirvonen R, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T1-2NO breast carcinoma. Breast Cancer Research and Treatment 2003;77:85-91.
• Kuittinen O, Apaja-Sarkkinen M & Turpeenniemi-Hujanen T. Gelatinases (MMP-2, MMP-9), TIMP-1 expression and the extent of neovascularisation in aggressive non-Hodgkin's lymphomas. Eur J Haematol 2003;71:91-99.
• Rahko E, Blanco G, Soini Y, Bloigu R, Jukkola A. Mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. European Journal of Cancer 2003;39:447-453.
• Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T . Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. British Journal of Cancer 2003;89:1270-1275.
• Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study. Clinical Cancer Research 2003;9:923-930.
• Gratwhol A, Baldomero H, et al. for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT) Finnish Group in Oulu: Koistinen P, Turpeenniemi-Hujanen T. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002;100:2374-2386.
• Gratwhol A, Baldomero H, et al. for the EMBT, ALWP, ELWP and the Lymphoma Working Party. Finnish Group in Oulu: Koistinen P, Turpeenniemi-Hujanen T. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 2003;17:941-959.
• Kuittinen O, Soini Y & Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol 2002;69(4):205-212.
• Kallio R, Bloigu A, Surcel H-M & Syrjälä H. C-reactive protein and erutyrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer 2001;9:124-128.
• Kallio R, Surcel H-M, Bloigu A & Syrjälä H. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer 2000;36;889-894.
• Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkänen L, Turpeenniemi-Hujanen T, Joensuu H. Ommission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. Journal of Clinical Oncology 2001;19(1):28-36.
• Ylisirniö S, Höyhtyä M, Mäkitaro R, Pääkkö P, Risteli J, Kinnula V, Turpeenniemi-Hujanen T, Jukkola A. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clinical Cancer Research 2001;7:1633-1637.
• Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E, Joensuu H. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Journal of Clinical Oncology 2000;18(20):3487-3494.
• Maiche AB, Jekunen AP, Kaleva-Kerola J, Blanco Sequeiros G. High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma. Cancer 2000;88(8):1863-1868.
• Bergh J, Wiklund T; et al. Scandinavian Breast Group 9401 study; Turpeenniemi-Hujanen T, Kuittinen O. Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer; a randomised trial. Lancet 2000;356:1384-1391.
  
  Paluu